tradingkey.logo

Eli Lilly and Co

LLY

748.190USD

-7.200-0.95%
Close 09/15, 16:00ETQuotes delayed by 15 min
708.41BMarket Cap
51.33P/E TTM

Eli Lilly and Co

748.190

-7.200-0.95%
More Details of Eli Lilly and Co Company

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

Company Info
Ticker SymbolLLY
Company nameEli Lilly and Co
IPO dateJul 09, 1970
CEOMr. David A. (Dave) Ricks
Number of employees47000
Security typeOrdinary Share
Fiscal year-endJul 09
AddressLilly Corporate Ctr
CityINDIANAPOLIS
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code46285
Phone13172762000
Websitehttps://www.lilly.com/
Ticker SymbolLLY
IPO dateJul 09, 1970
CEOMr. David A. (Dave) Ricks
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.32K
+2.17%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.32K
+2.17%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
3.84B
30.18%
Diabetes-Zepbound
2.31B
18.16%
Oncology-Verzenio
1.16B
9.10%
Diabetes-Trulicity
1.10B
8.60%
Diabetes-Jardiance
1.01B
7.97%
Other
3.31B
25.98%
By RegionUSD
Name
Revenue
Proportion
U.S.
8.49B
66.70%
Europe
2.39B
18.77%
Other foreign countries
997.40M
7.84%
China
450.80M
3.54%
Japan
402.20M
3.16%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
3.84B
30.18%
Diabetes-Zepbound
2.31B
18.16%
Oncology-Verzenio
1.16B
9.10%
Diabetes-Trulicity
1.10B
8.60%
Diabetes-Jardiance
1.01B
7.97%
Other
3.31B
25.98%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lilly Endowment, Inc.
10.12%
The Vanguard Group, Inc.
8.46%
PNC Investments LLC
5.40%
BlackRock Institutional Trust Company, N.A.
4.36%
State Street Global Advisors (US)
3.65%
Other
68.02%
Shareholders
Shareholders
Proportion
Lilly Endowment, Inc.
10.12%
The Vanguard Group, Inc.
8.46%
PNC Investments LLC
5.40%
BlackRock Institutional Trust Company, N.A.
4.36%
State Street Global Advisors (US)
3.65%
Other
68.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.59%
Investment Advisor/Hedge Fund
18.56%
Foundation
10.12%
Research Firm
1.97%
Pension Fund
1.91%
Bank and Trust
1.89%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.92%
Other
16.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 31, 2025
The Vanguard Group, Inc.
78.87M
8.32%
+4.97M
+6.73%
Mar 31, 2025
PNC Investments LLC
51.09M
5.39%
+1.95K
+0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
41.47M
4.38%
+359.58K
+0.87%
Mar 31, 2025
State Street Global Advisors (US)
34.44M
3.63%
+124.04K
+0.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
27.18M
2.87%
-2.17M
-7.40%
Mar 31, 2025
Capital Research Global Investors
15.75M
1.66%
+4.99M
+46.39%
Mar 31, 2025
Geode Capital Management, L.L.C.
18.53M
1.95%
+1.14M
+6.58%
Mar 31, 2025
Capital World Investors
18.38M
1.94%
-1.17M
-5.98%
Mar 31, 2025
T. Rowe Price Associates, Inc.
17.98M
1.9%
-1.75M
-8.89%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
Defiance Daily Target 2X Long LLY ETF
84.88%
iShares U.S. Pharmaceuticals ETF
20.57%
Harbor Health Care ETF
16.13%
Roundhill GLP-1 & Weight Loss ETF
15.57%
VanEck Pharmaceutical ETF
13.65%
Amplify Weight Loss Drug & Treatment ETF
12.82%
Proshares Ultra Health Care
12.54%
Health Care Select Sector SPDR Fund
12.53%
iShares U.S. Healthcare ETF
12.33%
Fidelity MSCI Health Care Index ETF
11.06%
View more
Defiance Daily Target 2X Long LLY ETF
Proportion84.88%
iShares U.S. Pharmaceuticals ETF
Proportion20.57%
Harbor Health Care ETF
Proportion16.13%
Roundhill GLP-1 & Weight Loss ETF
Proportion15.57%
VanEck Pharmaceutical ETF
Proportion13.65%
Amplify Weight Loss Drug & Treatment ETF
Proportion12.82%
Proshares Ultra Health Care
Proportion12.54%
Health Care Select Sector SPDR Fund
Proportion12.53%
iShares U.S. Healthcare ETF
Proportion12.33%
Fidelity MSCI Health Care Index ETF
Proportion11.06%
Dividend
A total of 18.06B USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI